K92 Mining Valuation
Is 92K undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 92K when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 92K (€6.35) is trading below our estimate of fair value (€65)
Significantly Below Fair Value: 92K is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 92K?
Key metric: As 92K is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 92K's PE Ratio? | |
|---|---|
| PE Ratio | 21x |
| Earnings | US$75.68m |
| Market Cap | US$1.59b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5x |
| Enterprise Value/EBITDA | 10.3x |
| PEG Ratio | 0.7x |
Price to Earnings Ratio vs Peers
How does 92K's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 27.7x | ||
NDA Aurubis | 8.9x | -6.2% | €3.3b |
SDF K+S | 79.2x | 61.1% | €2.0b |
STO3 Sto SE KGaA | 11.1x | 3.5% | €730.0m |
ACT AlzChem Group | 11.9x | 12.6% | €594.3m |
92K K92 Mining | 21x | 28.7% | €2.2b |
Price-To-Earnings vs Peers: 92K is good value based on its Price-To-Earnings Ratio (21x) compared to the peer average (27.7x).
Price to Earnings Ratio vs Industry
How does 92K's PE Ratio compare vs other companies in the European Metals and Mining Industry?
| 14 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 14 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 92K is expensive based on its Price-To-Earnings Ratio (21x) compared to the European Metals and Mining industry average (12.1x).
Price to Earnings Ratio vs Fair Ratio
What is 92K's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 21x |
| Fair PE Ratio | 21.9x |
Price-To-Earnings vs Fair Ratio: 92K is good value based on its Price-To-Earnings Ratio (21x) compared to the estimated Fair Price-To-Earnings Ratio (21.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €6.35 | €9.20 +44.7% | 15.6% | €10.99 | €6.87 | n/a | 11 |
| Nov ’25 | €6.28 | €8.82 +40.6% | 16.3% | €10.58 | €6.28 | n/a | 11 |
| Oct ’25 | €5.38 | €7.92 +47.2% | 14.2% | €9.99 | €6.00 | n/a | 11 |
| Sep ’25 | €4.91 | €7.75 +57.7% | 16.0% | €9.93 | €5.96 | n/a | 11 |
| Aug ’25 | €5.26 | €7.70 +46.4% | 15.3% | €9.50 | €6.00 | n/a | 11 |
| Jul ’25 | €5.31 | €7.69 +44.9% | 15.5% | €9.55 | €6.14 | n/a | 12 |
| Jun ’25 | €5.20 | €7.48 +43.9% | 14.3% | €9.45 | €6.08 | n/a | 12 |
| May ’25 | €5.00 | €7.32 +46.5% | 15.1% | €9.57 | €5.98 | n/a | 13 |
| Apr ’25 | €4.25 | €6.98 +64.2% | 17.5% | €9.52 | €5.44 | n/a | 13 |
| Mar ’25 | €4.05 | €6.92 +70.9% | 16.1% | €9.54 | €5.45 | n/a | 13 |
| Feb ’25 | €4.47 | €7.14 +60.0% | 14.5% | €9.54 | €5.62 | n/a | 13 |
| Jan ’25 | €4.51 | €7.05 +56.4% | 16.3% | €9.54 | €5.28 | n/a | 13 |
| Dec ’24 | €4.06 | €6.84 +68.6% | 16.9% | €9.38 | €5.19 | n/a | 12 |
| Nov ’24 | €3.28 | €7.28 +122.0% | 15.4% | €9.59 | €5.82 | €6.28 | 11 |
| Oct ’24 | €3.99 | €7.86 +97.4% | 15.5% | €9.59 | €5.82 | €5.38 | 12 |
| Sep ’24 | €4.34 | €7.77 +79.1% | 15.9% | €9.51 | €5.77 | €4.91 | 12 |
| Aug ’24 | €4.11 | €7.88 +91.7% | 15.7% | €9.62 | €5.84 | €5.26 | 12 |
| Jul ’24 | €3.96 | €8.07 +103.8% | 12.7% | €9.70 | €6.58 | €5.31 | 13 |
| Jun ’24 | €4.23 | €7.85 +85.9% | 12.7% | €9.42 | €6.39 | €5.20 | 13 |
| May ’24 | €4.28 | €7.85 +83.6% | 12.7% | €9.42 | €6.39 | €5.00 | 13 |
| Apr ’24 | €5.18 | €7.83 +51.0% | 12.3% | €9.52 | €6.29 | €4.25 | 13 |
| Mar ’24 | €5.24 | €8.02 +53.1% | 12.4% | €9.79 | €6.47 | €4.05 | 13 |
| Feb ’24 | €5.17 | €7.82 +51.2% | 12.9% | €9.64 | €6.37 | €4.47 | 13 |
| Jan ’24 | €5.11 | €7.87 +53.8% | 12.9% | €9.75 | €6.44 | €4.51 | 13 |
| Dec ’23 | €5.74 | €8.10 +41.1% | 13.1% | €10.13 | €6.69 | €4.06 | 12 |
| Nov ’23 | €4.71 | €8.34 +77.0% | 12.9% | €10.36 | €6.85 | €3.28 | 13 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
UBE
JP¥241.7b
Engages in the chemicals, construction materials, and machinery businesses in Japan, North America, Europe, Africa, the Middle East, Thailand, India, Latin America, and internationally.
UBE
JP¥15.30
7D
8.5%
1Y
7.7%
Tokuyama
JP¥197.6b
Produces and sells various chemical products in Japan.
TBT
JP¥16.70
7D
5.0%
1Y
16.0%
Mitsubishi Chemical Group
JP¥1.2t
Provides performance products, chemicals, industrial gases, health care products, and other products in Japan and internationally.
M3C
JP¥5.27
7D
2.9%
1Y
-8.1%